Replimune Group (NASDAQ:REPL) Price Target Raised to $21.00 at HC Wainwright

Replimune Group (NASDAQ:REPL - Get Free Report) had its price objective boosted by analysts at HC Wainwright from $17.00 to $21.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has a "buy" rating on the stock. HC Wainwright's target price suggests a potential upside of 61.29% from the company's previous close.

A number of other research firms have also weighed in on REPL. JPMorgan Chase & Co. raised their price objective on Replimune Group from $14.00 to $17.00 and gave the company an "overweight" rating in a research report on Tuesday, September 24th. BMO Capital Markets raised their price objective on Replimune Group from $14.00 to $18.00 and gave the company an "outperform" rating in a research report on Friday, November 22nd. Finally, Jefferies Financial Group raised their price objective on Replimune Group from $16.00 to $19.00 and gave the company a "buy" rating in a research report on Wednesday, December 4th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Replimune Group currently has an average rating of "Buy" and a consensus target price of $19.14.

Replimune Group Trading Up 9.9 %

REPL stock traded up $1.17 during trading on Wednesday, hitting $13.02. 1,465,585 shares of the company traded hands, compared to its average volume of 905,541. The firm has a market capitalization of $890.83 million, a PE ratio of -4.27 and a beta of 1.28. Replimune Group has a 1 year low of $4.92 and a 1 year high of $17.00. The company has a 50-day moving average of $12.16 and a 200-day moving average of $11.24. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.11 and a current ratio of 10.11.

Replimune Group (NASDAQ:REPL - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.07. Analysts predict that Replimune Group will post -2.91 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Replimune Group news, CEO Sushil Patel sold 10,000 shares of the company's stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $12.42, for a total transaction of $124,200.00. Following the sale, the chief executive officer now directly owns 202,014 shares in the company, valued at $2,509,013.88. This represents a 4.72 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Konstantinos Xynos sold 7,246 shares of the company's stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $10.78, for a total value of $78,111.88. Following the sale, the insider now owns 109,885 shares in the company, valued at approximately $1,184,560.30. This trade represents a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 8.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On Replimune Group

Hedge funds and other institutional investors have recently modified their holdings of the business. Charles Schwab Investment Management Inc. grew its stake in Replimune Group by 12.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 484,797 shares of the company's stock worth $5,313,000 after purchasing an additional 52,498 shares in the last quarter. Geode Capital Management LLC grew its stake in Replimune Group by 17.9% in the third quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company's stock worth $15,657,000 after purchasing an additional 217,308 shares in the last quarter. Barclays PLC grew its stake in Replimune Group by 165.5% in the third quarter. Barclays PLC now owns 158,491 shares of the company's stock worth $1,738,000 after purchasing an additional 98,791 shares in the last quarter. LMR Partners LLP grew its stake in Replimune Group by 145.8% in the third quarter. LMR Partners LLP now owns 82,479 shares of the company's stock worth $904,000 after purchasing an additional 48,920 shares in the last quarter. Finally, Cubist Systematic Strategies LLC grew its stake in Replimune Group by 282.2% in the second quarter. Cubist Systematic Strategies LLC now owns 72,207 shares of the company's stock worth $650,000 after purchasing an additional 53,313 shares in the last quarter. 92.53% of the stock is currently owned by hedge funds and other institutional investors.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.